Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) in men with metastatic castration-resistant prostate cancer. The clinical-stage biopharmaceutical company presented the study results at the European Society for Medical Oncology meeting in Berlin, revealing significant clinical benefit in 86% of patients treated with ENV-105 combined with apalutamide.

The study demonstrated that all responders remained progression-free for at least four months, with half of the patients maintaining progression-free status beyond one year. Among the nine evaluable patients, seven experienced PSA reductions, supporting the therapy's potential to restore hormone responsiveness in this difficult-to-treat patient population. The randomized trial, led by Cedars-Sinai and partner institutions, continues to enroll patients to further evaluate safety and long-term efficacy.

This development is particularly significant because metastatic castration-resistant prostate cancer represents a critical treatment challenge where patients typically develop resistance to standard therapies. The high clinical benefit rate observed in this interim analysis suggests ENV-105 could potentially address the substantial unmet medical need in this patient population. Prostate cancer remains one of the most common cancers in men worldwide, and the castration-resistant form often leads to limited treatment options and poor outcomes.

ENV-105 represents an innovative approach to cancer treatment as an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy results in resistance and disease relapse. The therapy aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

The positive interim results could have broader implications for cancer treatment beyond prostate cancer, as the mechanism of action targeting CD105-mediated resistance might be applicable to other cancer types where treatment resistance develops. Currently, ENV-105 is also being evaluated in a Phase 1 trial for lung cancer, addressing additional significant unmet medical needs in oncology. The continued enrollment in the Phase 2 trial will provide more comprehensive data on the therapy's safety profile and long-term efficacy, which will be crucial for determining its potential clinical utility and regulatory pathway.